Scrip
Amgen's Vectibix meets goal in pivotal first-line trial in colorectal cancer
07 August 2009
Malini Guha
Amgen's EGFR-targeted human monoclonal antibody, Vectibix (panitumumab), has met its primary progression-free survival (PFS) endpoint in its pivotal Phase III trial, PRIME, in patients with newly diagnosed metastatic colorectal cancer (mCRC) who have a wild-type KRAS gene.
Detailed efficacy and...
Please Login to read the full article.
07 August 2009
Malini Guha
Detailed efficacy and...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Mixed Phase III results for Erbitux in first-line colorectal cancer
- Vectibix clears PFS but survival hurdle still awaits in colorectal cancer
- Amgen's Vectibix fails to show survival benefit in pivotal first-line trial in colorectal cancer
- New US labelling for Erbitux and Vectibix recommends against their use for large subset of colorectal cancer patients
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
